Results 41 to 50 of about 189 (150)

Future Prospects of Imatinib in Advanced Pulmonary Hypertension Management

IUBMB Life, Volume 78, Issue 3, March 2026.
ABSTRACT Pulmonary arterial hypertension (PAH) is a severe, progressive disease characterized by elevated pulmonary arterial pressure and increased vascular resistance. This hemodynamic strain forces the right ventricle to pump against a high‐pressure system, ultimately leading to right‐sided heart failure and death.
Federica Davì, Stella Mangione, Antonella Iaconis, Tiziana Genovese, Nicla Tranchida, Salvatore Cuzzocrea   +5 more
wiley   +1 more source

Quantitative biomonitoring of polycyclic aromatic compounds (PACs) using the Sydney rock oyster (Saccostrea glomerata) [PDF]

, 2020
Increasing our understanding of the bioavailable fractions of polycyclic aromatic compounds (PACs) in an aquatic environment is important for the assessment of the environmental and human health risks posed by PACs.
Webster, Grant, Semple, Kirk, O'Connor, Wayne, Chapman, Ian, Kim Anh Tran, Thi, Hansbro, Phil, Baker, Phil, Zammit, Anthony, Thavamani, Palanisami, Idowu, Oluyoye, Farrel, Hazel   +10 more
core  

Plasma GDF‐15 and PSP‐D Predict the Development of Pulmonary Arterial Hypertension in Systemic Sclerosis

Pulmonary Circulation, Volume 16, Issue 1, January 2026.
ABSTRACT Patients with pulmonary arterial hypertension (PAH) experience long diagnostic delays, high functional class at diagnosis and poor prognosis. We aimed to study the differentiative and predictive value of 90 inflammatory and immunomodulatory related proteins in idiopathic and hereditary PAH (IPAH/HPAH) and systemic sclerosis‐associated PAH (SSc‐
Adam Engel Sällberg, Salaheldin Ahmed, Abdulla Ahmed, Kriss Kania, Jørn Carlsen, Roger Hesselstrand, Kristofer Andréasson, Göran Rådegran   +7 more
wiley   +1 more source

Identification of Key Genes and Pathways Associated With Gender Differences in Pulmonary Arterial Hypertension Based on Bioinformatic Approaches

BioMed Research International, Volume 2026, Issue 1, 2026.
Pulmonary arterial hypertension (PAH) is a complex disease with multiple contributing factors. Epidemiological data showed that women are more susceptible to PAH, but they tend to have better right ventricular (RV) function and prognosis compared to men. The mechanisms behind these gender differences are not well understood.
Mohammad Panahi, Reyhaneh Kalhor, Mohammad-Hossein Mokhtarian, Fatemeh Javaheri Tehrani, Zinat Shams, Hourieh Kalhor, Hannah Wesley   +6 more
wiley   +1 more source

Advances in Novel Therapeutic Strategies for Pulmonary Arterial Hypertension

Canadian Respiratory Journal, Volume 2026, Issue 1, 2026.
Pulmonary arterial hypertension (PAH) is a progressive, life‐threatening disease characterized by vascular remodeling, endothelial dysfunction, and chronic inflammation. Despite existing targeted therapies, long‐term outcomes remain poor, underscoring the need for more effective treatment.
Yalei Wang, Jiacheng Wu, Qian Ma, Hao Chen, Erha Lama, Yulu Yang, Jianwu Huang, Changhu Liu, Xiaofei Ni, Zhihua Qiu, Zihua Zhou, Sami Deniz   +11 more
wiley   +1 more source

Geochemical indices describing PAHs in vegetation and soil in the outskirt of Xi’an.

, 2015
The soil samples and vegetable samples were labeled by S and V, respectively. LPAHs/HPAHs, the ratio of the sum of 2- to 3-ring PAHs with low molecular weight to the sum of 4- to 6-ring PAHs with high molecular weight; Phe, phenanthrene; Ant, anthracene;
Juan Zhang (48597), Juncheng Yang (697743), Wenyan Wang (171659), Xiaoming Du (697742), Shukai Fan (697741), Hong Hou (697744)   +5 more
core   +1 more source

Late Onset Pulmonary Arterial Hypertension Associated With Features of Pulmonary Veno‐Occlusive Disease and Rare Heterozygous Variants of KDR and EIF2AK4

Pulmonary Circulation, Volume 15, Issue 4, October 2025.
ABSTRACT The natural history of late‐onset pulmonary arterial hypertension (PAH) with features of venous/capillary involvement and the associations with rare variants in PAH genes are not well known. We report a case of a female patient who developed severe PAH at the age of 70.
Vasile Foris, Luka Brcic, Peter Dorfmüller, Christina A. Eichstaedt, Ekkehard Grünig, Philipp Douschan, Teresa John, Katarina Zeder, Michael Fuchsjäger, Nikolaus Kneidinger, Gabor Kovacs, Horst Olschewski   +11 more
wiley   +1 more source

American Lung Association Pulmonary Hypertension Roundtable: Executive Summary

Pulmonary Circulation, Volume 15, Issue 4, October 2025.
ABSTRACT The American Lung Association and Pulmonary Hypertension Association convened a scientific roundtable of pulmonary hypertension experts to discuss the latest recommendations from the European Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension (PH) and from the 7th World Symposium on Pulmonary Hypertension (WSPH).
Nicholas Andreas Kolaitis, Sandeep Sahay, Erika Berman Rosenzweig, Deborah Brown, Anna Hemnes, Elizabeth Joseloff, Joy Meyer, Karen A. Pescatore, Albert Rizzo, Namita Sood, Bev Stewart, Vallerie McLaughlin, Tim Williamson, James R. Klinger   +13 more
wiley   +1 more source

Increased contractility affects left ventricular kinetic energy in pulmonary hypertension

Physiological Reports, Volume 13, Issue 17, September 2025.
Abstract Precapillary pulmonary hypertension (PH) is characterized by increased pulmonary vascular resistance (PVR), with progressively altered right (RV) and left ventricular (LV) hemodynamics and function. Kinetic energy (KE) from 4D flow cardiovascular magnetic resonance (CMR) is a measure of intracardiac hemodynamics.
E. Bergström, K. Pola, B. Kjellström, J. Töger, P. M. Arvidsson, M. Carlsson, G. Rådegran, H. Arheden, E. Ostenfeld   +8 more
wiley   +1 more source

Pharmacologic Management of Segmental Pulmonary Hypertension in Children After Unifocalization and Pulmonary Artery Reconstruction: Initial Experience

Pulmonary Circulation, Volume 15, Issue 3, July 2025.
ABSTRACT Segmental pulmonary hypertension (PH) in congenital heart disease remains poorly understood with data limited to case studies. We performed a retrospective, single center study in children treated with PH medications after unifocalization/pulmonary artery reconstruction for major aortopulmonary collaterals (MAPCA). Drug response was determined
Julian E. Cameron, Doff B. McElhinney, Esther Liu, Rachel K. Hopper, Ritu Asija, Manchula Navaratnam, Frank L. Hanley, Jeffrey A. Feinstein   +7 more
wiley   +1 more source